Showing posts with label H3N2. Show all posts
Showing posts with label H3N2. Show all posts

Tuesday, July 14, 2009

Swine Flu Vaccine Delayed: Further tests on swine flu victims

Whilst the world waits, anxiously for the new vaccine against this outbreak of Swine Flu, news of further delays in production and testing come to light.
Meanwhile the number of victims and fatalities increase.
Further post-mortem tests are to take place this week, to determine the causes of death of a six-year-old girl and a GP who both died after contracting the disease.

Chloe Buckley, from north west London, and Bedfordshire GP, Dr Michael Day, died after suffering from the virus. Their deaths took the number of UK deaths linked to swine flu to 17.

On Monday health bodies, the British Medical Association (BMA) and the The Royal College of General Practitioners, urged the public not to panic.

Chloe died last Thursday at St Mary's Hospital in Paddington. A post-mortem is due to be carried out to determine if she had underlying health conditions.

Dr Day died on Saturday in the Luton and Dunstable Hospital. A subsequent swab test revealed he had swine flu although it is not yet known if this was the cause of his death.

Health Secretary Andy Burnham said the UK was well placed to deal with the outbreak but could not rule out further deaths.

He said: "Although the swine flu virus is proving generally mild in most people, in some cases it is more severe. Unfortunately, as with seasonal flu, people may develop complications and in some cases will die."

The first British patient without underlying health problems died on Friday after contracting swine flu. The patient, from Essex, died in Basildon.
Nearly 10,000 Britons have been confirmed with the swine flu infection but hundreds of thousands more are thought to have the virus.
Confirmed sufferers are dosed with Tamiflu and confined to their home with minimal or no contact with the outside world.

Friday, July 10, 2009

H1N! Swine Flu Devastating South America

A passenger takes precautions at Ezeiza International Airport, Argentina, as the swine flu pandemic intensifies (Image: Daniel Garcia / AFP / Getty Images)

A passenger takes precautions at Ezeiza International Airport, Argentina, as the swine flu pandemic intensifies (Image: Daniel Garcia / AFP / Getty Images)

THE swine flu pandemic is intensifying in South America and finding little resistance. The US White House will meet with state representatives on 9 July to discuss preparations for the autumn flu season in the US. The UK has shifted its response from protection, to dealing with the impact of widespread infection in the UK.

Meanwhile, in South America, in the midst of its winter flu season, swine H1N1 virus seems to be replacing the seasonal flu viruses that circulated till now, a classic pandemic behaviour. This raises further concerns that seasonal flu vaccine, which some companies are still making, may be useless when the northern hemisphere's flu season arrives later this year.

In the flu pandemics of 1918, 1957 and 1968, the pandemic virus completely replaced the circulating seasonal flu but in 1977, an accidentally released mild H1N1 virus simply circulated alongside the existing flu, H3N2. So, no one is sure how this swine flu H1N1 will behave. It is overwhelming what is not known about this influenza and its potential devastating impact on the civilised world.

If it does not replace the seasonal viruses - the milder H1N1 and the H3N2 - the world faces the prospect of being infected by all three viruses at once. This would be a very complicated and dangerous scenario: both seasonal and pandemic vaccines would be needed and differing age groups of people would be affected. Let's hope that what is happening in South America, is not indicative of this influenza's emerging profile.

In North America, swine flu also dominates: as expected, more than 98 per cent of flu cases genotyped in the US in late June were caused by the pandemic virus. While seasonal flu viruses normally die out in the summer, the pandemic virus has the advantage that few people have any immunity to it.